Seagen (NASDAQ:SGEN) & ImmunityBio (NASDAQ:IBRX) Head to Head Review

Seagen (NASDAQ:SGENGet Rating) and ImmunityBio (NASDAQ:IBRXGet Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Earnings and Valuation

This table compares Seagen and ImmunityBio’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Seagen $1.57 billion 15.54 -$674.47 million ($3.45) -38.19
ImmunityBio $930,000.00 2,268.37 -$346.79 million N/A N/A

ImmunityBio has lower revenue, but higher earnings than Seagen.

Profitability

This table compares Seagen and ImmunityBio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Seagen -34.16% -21.56% -17.46%
ImmunityBio -71,743.44% N/A -104.67%

Volatility and Risk

Seagen has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Seagen and ImmunityBio, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seagen 0 3 11 0 2.79
ImmunityBio 0 0 1 0 3.00

Seagen presently has a consensus price target of $162.18, indicating a potential upside of 23.08%. ImmunityBio has a consensus price target of $9.00, indicating a potential upside of 70.78%. Given ImmunityBio’s stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Seagen.

Institutional and Insider Ownership

88.2% of Seagen shares are owned by institutional investors. Comparatively, 8.3% of ImmunityBio shares are owned by institutional investors. 27.3% of Seagen shares are owned by company insiders. Comparatively, 79.7% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

ImmunityBio beats Seagen on 7 of the 12 factors compared between the two stocks.

About Seagen

(Get Rating)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

About ImmunityBio

(Get Rating)

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.